Steven A. Boyd

VenatoRx Pharmaceuticals (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes”.

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.1c00437

N/A

0DataRank · unranked

47 citations

Allison L. Zulli, Eugen F. Mesaros, Randy W. Jackson, Steven A. Boyd, Bin Liu +13 more

A new class of penicillin-binding protein inhibitors to address drug-resistant Neisseria gonorrhoeae

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.12.27.630553

N/A

0DataRank · unranked

1 citations

Allison L. Zulli, Brittany Miller, Lindsay M. Avery, Steven A. Boyd, Cassandra L. Chatwin +25 more